MS International (AIM: MSI) — Initiation of Coverage (Refresh)

   The Quick Take Company: MS International (AIM: MSI) — a UK family-controlled engineering group built around MSI-Defence Systems, a tier-one supplier of naval gun systems and counter-drone air defence to global navies and land forces, with three legacy civilian divisions (Forgings, Petrol Station Superstructures, Corporate Branding) now formally being readied for disposal Thesis: A […]

Ondine Biomedical (AIM: OBI) — Initiation of Coverage

The Quick Take Company: Ondine Biomedical (AIM: OBI) — Canadian life-sciences group commercialising Steriwave®, a non-antibiotic nasal photodisinfection therapy Thesis: Asymmetric, catalyst-driven AIM venture bet on the first FDA-approvable nasal decolonisation product, anchored by HCA Healthcare’s strategic alignment as trial partner, equity holder and intended commercial channel; UK adoption via Mölnlycke supplies validation but is […]

Q1 26 Performance update

Q1 Portfolio Update: Navigating Multiple Compression and Sector Rotation The first quarter was defined by a ruthless recalibration of equity risk premiums. Against a challenging macroeconomic backdrop, capital rotated aggressively out of long-duration growth assets and into businesses offering tangible near-term cash flows, robust balance sheets, and pricing power. The portfolio generated an average total […]

AMS full year results

Overall, this is a highly reassuring statement. The company has successfully navigated the complexities of its transformational acquisitions (Peters Surgical and Syntacoll) while maintaining top-line momentum in its legacy portfolio. Excellent cash generation which allows for the reduction of debt. I think this would be acquired by a private equity in the next 1 year […]

Warpaint London (W7L): A High-Margin Compounder Consolidating the UK Beauty Market

For investors hunting for high-quality, cash-generative compounding machines on the AIM market, Warpaint London PLC (AIM: W7L) has long been a standout name. Historically known for its flagship “dupe” cosmetics brands, W7 and Technic, the company has carved out a highly profitable niche by offering premium-style beauty products at mass-market price points. However, as we […]

Hilton results

Another set of disappointing results. Not too surprising given the new CEO(its fairly common to get all the bad news out before he gets into the job). I will be exiting this holding as this is the third time they had a miss. I suspect they will sell off the fish division and I wouldn’t […]

Transense

I usually do not comment on companies in which I no longer have holdings, however I felt an inclination for this one given I’ve held it for a couple of years and the results were so shocking. The share price was down close to 35% on the day due to slowdown in revenue and reduction […]

Cordel

Terrible interim results. Despite the brokers reiterating guidance and talking about the expanded pipeline I have exited my position as I think I got this one wrong. As someone told me before, better to get off the runaway of a plane which will eventually crash. 40% loss on that one since purchase on a weighted […]